Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
BMC Pharmacol Toxicol ; 23(1): 94, 2022 12 21.
Article in English | MEDLINE | ID: mdl-36539885

ABSTRACT

PURPOSE: The aim of this work was to investigate the association between anticholinergic burden or anticholinergic drug use and xerostomia and/or xerophtalmia in elderly through a systematic review of the published literature. METHODS: A search was carried out in 3 databases (CINAHL, Embase and Pubmed). Studies conducted in people ≥65 years of age, who took anticholinergic medications, and measured the association between the anticholinergic burden or the use of these medications with the prevalence of xerostomia and / or xerophthalmia, published up to August 2022, were selected. Studies published in languages other than Spanish and/or English were excluded. RESULTS: One thousand two hundred eleven articles were identified, 10 were selected for this review: six cross-sectional studies, two cohorts, one case-control and one randomized controlled clinical trial. A total of 3535 patients included in the different studies were studied. The most used scales were the Anticholinergic Drug Scale (ADS) and the Anticholinergic Risk Scale (ARS). Four articles studied the relationship between the use of anticholinergic medication and the prevalence of xerostomia and / or xerophthalmia, finding a positive relationship with xerostomia in all of them. Another 6 measured the relationship between anticholinergic burden and xerostomia and / or xerophthalmia. Four found a positive relationship between anticholinergic burden and xerostomia and/or xerophthalmia. CONCLUSIONS: Our findings suggest a clear relationship between the use of anticholinergic drugs or anticholinergic burden and the presence of xerostomia. This relationship was less conclusive in the case of xerophthalmia.


Subject(s)
Xerophthalmia , Xerostomia , Humans , Aged , Cholinergic Antagonists/adverse effects , Xerophthalmia/drug therapy , Cross-Sectional Studies , Xerostomia/chemically induced , Xerostomia/epidemiology , Xerostomia/drug therapy , Prevalence , Randomized Controlled Trials as Topic
3.
Food Funct ; 5(6): 1270-7, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24740524

ABSTRACT

Extra virgin olive oil (EVOO) is obtained from the fruit of the olive tree Olea europaea L. Phenolic compounds present in EVOO have recognized anti-oxidant and anti-inflammatory properties. However, the activity of the total phenolic fraction extracted from EVOO and the action mechanisms involved are not well defined. The present study was designed to evaluate the potential anti-inflammatory mechanisms of the polyphenolic extract (PE) from EVOO on LPS-stimulated peritoneal murine macrophages. Nitric oxide (NO) production was analyzed by the Griess method and intracellular reactive oxygen species (ROS) by fluorescence analysis. Moreover, changes in the protein expression of the pro-inflammatory enzymes, inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2 and microsomal prostaglandin E synthase-1 (mPGES-1), as well as the role of nuclear transcription factor kappa B (NFκB) and mitogen-activated protein kinase (MAPK) signalling pathways, were analyzed by Western blot. PE from EVOO reduced LPS-induced oxidative stress and inflammatory responses through decreasing NO and ROS generation. In addition, PE induced a significant down-regulation of iNOS, COX-2 and mPGES-1 protein expressions, reduced MAPK phosphorylation and prevented the nuclear NFκB translocation. This study establishes that PE from EVOO possesses anti-inflammatory activities on LPS-stimulated murine macrophages.


Subject(s)
Lipopolysaccharides/adverse effects , Macrophages, Peritoneal/drug effects , NF-kappa B/genetics , Plant Oils/pharmacology , Polyphenols/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Antioxidants/pharmacology , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Down-Regulation , Intramolecular Oxidoreductases/genetics , Intramolecular Oxidoreductases/metabolism , MAP Kinase Signaling System , Macrophages, Peritoneal/metabolism , Male , Mice , Mitogen-Activated Protein Kinases/genetics , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , Olea/chemistry , Olive Oil , Phosphorylation , Prostaglandin-E Synthases , Reactive Oxygen Species/metabolism
4.
Br J Pharmacol ; 171(1): 134-44, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24116971

ABSTRACT

BACKGROUND AND PURPOSE: Increasing evidence demonstrates that melatonin regulates inflammatory and immune processes acting as both an activator and inhibitor of these responses. Nevertheless, the molecular mechanisms of its anti-inflammatory action remain unclear. Here we have characterized the cellular mechanisms underlying the redox modulation of LPS-stimulated inflammatory responses in murine peritoneal macrophages by melatonin to provide insight into its anti-inflammatory effects. EXPERIMENTAL APPROACH: Murine peritoneal macrophages were isolated and treated with melatonin in the presence or absence of LPS (5 µg·mL(-1) ) for 18 h. Cell viability was determined using sulforhodamine B assay and NO production was measured using the Griess reaction. Pro-inflammatory enzymes and transcription factors were detected by Western blotting. KEY RESULTS: Without affecting cell viability, melatonin (12.5, 25, 50 and 100 µM) reduced the level of nitrites, inducible NOS (iNOS), COX-2 and microsomal PGE synthase-1 (mPGES1) protein, and p38 MAPK phosphorylation, and prevented NF-κB translocation. Furthermore, melatonin treatment significantly increased NF-E2-related factor 2 (Nrf2) and haem oxygenase 1 (HO1) protein levels in murine macrophages exposed to LPS. CONCLUSIONS AND IMPLICATIONS: Melatonin reduced pro-inflammatory mediators and enhanced the expression of HO1 via NF-κB, p38 MAPK and Nrf2 cascade signalling pathways in murine macrophages. Thus, melatonin might be a promising target for diseases associated with overactivation of macrophages.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Antioxidants/metabolism , Intramolecular Oxidoreductases/metabolism , Lipopolysaccharides/pharmacology , Macrophages, Peritoneal/drug effects , Melatonin/pharmacology , NF-E2-Related Factor 2/metabolism , Animals , Cell Survival/drug effects , Cells, Cultured , Cyclooxygenase 2/metabolism , Dose-Response Relationship, Drug , Heme Oxygenase-1/genetics , Heme Oxygenase-1/metabolism , Macrophage Activation/drug effects , Macrophages, Peritoneal/enzymology , Macrophages, Peritoneal/immunology , Male , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mice , NF-kappa B/metabolism , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/metabolism , Nitrites/metabolism , Phosphorylation , Prostaglandin-E Synthases , Signal Transduction/drug effects , Time Factors , Transcription, Genetic/drug effects , p38 Mitogen-Activated Protein Kinases/metabolism
5.
J Ethnopharmacol ; 149(1): 140-7, 2013 Aug 26.
Article in English | MEDLINE | ID: mdl-23792124

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Abarema cochliacarpos (Gomes) Barneby and Grimes (Fabaceae), known by the vulgar name of Babatenã, has been traditionally used in Northeast Brazil, as an anti-inflammatory remedy. Previous studies have demonstrated its anti-inflammatory and antiulcer effects in skin lesion, alcohol gastric ulcer and acute and chronic colitis. AIMS: The present study was designed to evaluate the antioxidant and anti-inflammatory effects of the butanolic fraction from A. cochliacarpos (BFAC) and its major flavonoid, (+)-catechin, in LPS-stimulated murine peritoneal macrophages. Moreover, we studied the role of mitogen-activated protein kinase (MAPK)s and NF-kB signaling pathways possibly involved in the beneficial effects. MATERIALS AND METHODS: The quantification of the extract was carried out by ultra-performance liquid chromatography analysis. Cell viability was determined using SRB assay. Nitric oxide (NO) production was analyzed by Griess method and intracellular reactive oxygen species (ROS) by fluorescence analysis. In addition, cyclooxygenase (COX-2) and inducible nitric oxide synthase (iNOS) expression, MAPK activation and IkappaBalpha (IKBα) degradation, were determined by Western blot. RESULTS: After BFAC characterization, (+)-catechin was revealed as its major constituent. Both BFAC and (+)-catechin, exerted significant anti-oxidant and anti-inflammatory effects inhibiting LPS-induced intracellular ROS and NO production in peritoneal macrophages. Additionally, the extract but also its major component reduced pro-inflammatory proteins expression probably through c-Jun N-terminal kinase and p38 MAPK signaling pathways. CONCLUSION: These data suggest that the beneficial effects of BFAC might be mediated, at least in part, by the presence of (+)-catechin. Conclusively our findings confirm the potential of A. cochliacarpos as a new therapeutic strategy for the management of inflammatory and oxidative stress-related diseases.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Fabaceae/chemistry , MAP Kinase Signaling System/drug effects , Macrophages, Peritoneal/drug effects , Plant Extracts/pharmacology , Reactive Oxygen Species/metabolism , Animals , Anti-Inflammatory Agents/isolation & purification , Brazil , Cell Survival/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Ethnopharmacology , Lipopolysaccharides/pharmacology , Macrophages, Peritoneal/enzymology , Macrophages, Peritoneal/immunology , Mice , Plant Extracts/isolation & purification , Spectrometry, Mass, Electrospray Ionization
6.
Eur J Pharm Sci ; 48(3): 572-81, 2013 Feb 14.
Article in English | MEDLINE | ID: mdl-23238173

ABSTRACT

Extra virgin olive oil (EVOO) has demonstrated immunomodulatory and antiinflammatory properties in murine experimental ulcerative colitis (UC). In addition to its high monounsaturated fatty acid content, evidences have accumulated on the favorable properties of minor, although highly bioactive, components present in the unsaponifiable fraction (UF). The present study was designed to evaluate the effects of dietary EVOO's UF supplementation on acute UC. C57BL/6 mice were fed from weaning with sunflower oil (SD), EVOO diet and UF-enriched SD at 5% oil (SD+UF). After 30 days, mice were exposed to 3% dextran sulfate sodium (DSS) for 5 days developing acute colitis. After 4 days of DSS removal, animals were sacrificed and colons were histological and biochemically processed. Disease activity index and microscopic damage score were significantly improved in EVOO and SD+UF dietary groups versus SD group. In addition, both dietary treatments significantly induced decreases in MCP-1 and TNF-α levels, iNOS and COX-2 overexpression and p38 MAPKs activation in colon mucosa. Moreover, an upregulation of IκB expression was also observed after feeding the animals with both diets. However, no statistically differences between data from mice fed with EVOO or UF+SD diets were observed. Dietary enrichment with EVOO's UF reduces the damage in acute colitis model, alleviating the oxidative events and returning proinflammatory proteins expression to basal levels probably through p38 MAPK and NFκB signalling pathways. EVOO's UF diet might provide a basis for developing a new strategy in dietary supplementation for the prevention of UC.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Colitis, Ulcerative/prevention & control , Colon/immunology , Dietary Supplements , Intestinal Mucosa/immunology , Plant Extracts/therapeutic use , Plant Oils/chemistry , Animals , Chemokine CCL2/antagonists & inhibitors , Chemokine CCL2/genetics , Chemokine CCL2/metabolism , Colitis, Ulcerative/immunology , Colitis, Ulcerative/metabolism , Colitis, Ulcerative/pathology , Colon/metabolism , Colon/pathology , Cyclooxygenase 2/chemistry , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Enzyme Activation , Female , Gene Expression Regulation , Hydrolysis , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Mice, Inbred C57BL , Nitric Oxide Synthase Type II/antagonists & inhibitors , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , Olive Oil , Plant Oils/standards , Random Allocation , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism , Weaning , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/metabolism
7.
Curr Med Chem ; 19(15): 2414-41, 2012.
Article in English | MEDLINE | ID: mdl-22455589

ABSTRACT

In the last years, studies about longevity have highlighted that caloric restriction can be linked with a less normal agingassociated damage, and in the same way, with the activity of the Silent Information Regulator 2 (SIR2) gene. Sir2-like genes, known as sirtuins (SIRTs), have been found in organisms ranging from bacteria to mammals promoting health and survival. At the moment, it has been identified seven classes of SIRTs in mammalian and the understanding of many of them remains still rudimentary. However, they are in the spotlight by their potential protection against aging-associated diseases and have emerged as key mediators of longevity in evolutionarily distant organisms models. SIRTs are proteins found in numerous compartments within the cell, which are NAD(+)-dependent protein deacetylases and adenosine diphosphate (ADP)-ribosyltransferases. They catalyse a reaction in which NAD(+) and an acetylated substrate are converted into a deacetylated substrate, nicotinamide and a novel metabolite O-acetyl ADP ribose. Therefore, its enzymatic activity requires NAD(+), which is a crucial molecule intermediary of many metabolic reactions in cells. Basically, SIRTs are mediators of aging process, they have the potential of ameliorating and taking part in important cellular processes associated, such as metabolic homeostasis, tumorigenesis and cancer cell proliferation, inflammatory disorders, cardiovascular diseases and neurodegeneration. This background opens up new lines of investigation into the modulation of SIRTs activity in order to develop novel therapeutic targets to these age-related diseases. Current experiments using molecule activators or inhibitors and genetically engineered animals have facilitated new insights into the role of these enzymes and contributed to highlight some of the potentially relevant targets. This review is intended to provide an appreciation of the possible protection against aging-associated diseases by these enzymes, summarize novel underlying mechanisms and evaluate potential clinical applications.


Subject(s)
Longevity/physiology , Sirtuins/antagonists & inhibitors , Sirtuins/metabolism , Age Factors , Animals , Humans , Metabolic Diseases/drug therapy , Metabolic Diseases/metabolism , Neurodegenerative Diseases/drug therapy , Neurodegenerative Diseases/metabolism , Sirtuins/genetics
8.
Inflamm Bowel Dis ; 17(3): 696-710, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20722052

ABSTRACT

BACKGROUND: Colorectal cancer (CRC) is the most severe complication in inflammatory bowel disease (IBD). In the present study we investigated different mechanistic links between chronic colonic inflammation and its progression to adenocarcinoma. Along these lines, given that adrenomedullin (AM) has been implicated in carcinogenesis, we also analyzed changes in its colonic expression. METHODS: Mice were exposed to 5, 10, and 15 cycles of dextran sulfate sodium (DSS); each cycle consisted of 0.7% DSS for 1 week followed by distilled water for 10 days. After each period, macroscopic and histological studies, as well as characterization of inflammatory and tumor biomarkers, were carried out. RESULTS: The disease activity index (DAI) showed that the disease was present from the third cycle and it gradually increased during the course of DSS treatment. Macroscopic tumors were only seen after 15 cycles, and microscopic study showed that inflammation, dysplasia, and adenocarcinomas correlated with DSS cycles. ß-Catenin and proliferating cell nuclear antigen expressions progressively increased in animals treated with the different cycles of DSS. TNF-α and IFN-γ showed the highest production at the tenth cycle. COX-2, mPGES-1, and iNOS levels were also appreciably higher at the fifth and tenth cycles. Moreover, we observed a progressive enhancement in AM expression and changes in its intracellular location during the progression of the disease. CONCLUSIONS: Our results show an early induction of proinflammatory factors, which may contribute to the development of colon cancer, as well as demonstrate, for the first time, the expression of AM in IBD-derived CRC.


Subject(s)
Adenocarcinoma/metabolism , Biomarkers, Tumor/metabolism , Colitis, Ulcerative/metabolism , Colorectal Neoplasms/metabolism , Adenocarcinoma/pathology , Adrenomedullin/metabolism , Animals , Blotting, Western , Cell Transformation, Neoplastic/metabolism , Chronic Disease , Colitis, Ulcerative/chemically induced , Colorectal Neoplasms/pathology , Cytokines/metabolism , Dextran Sulfate/toxicity , Female , Immunoenzyme Techniques , Mice , Mice, Inbred C57BL , Tumor Necrosis Factor-alpha/metabolism , beta Catenin/metabolism
9.
Clin Nutr ; 29(5): 663-73, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20427102

ABSTRACT

BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) are at increased risk for developing ulcerative colitis (UC)-associated colorectal cancer (CRC). Several studies have shown that extra virgin olive oil (EVOO) might possess anti-inflammatory, antiproliferative and antiapoptotic effects. We have evaluated EVOO diet effects on the severity of repeated colitis-associated CRC. METHODS: Six-week-old C57BL/6 mice were randomized into two dietary groups: sunflower oil (SFO) and EVOO diets, both at 10%. Mice were exposed to 15 cycles of 0.7% dextran sodium sulphate (DSS) for 1 week followed by distilled water for 10 days. After, the rats were sacrificed and colonic damage was both histologically and biochemically assessed. RESULTS: Disease activity index (DAI) was significantly higher on SFO vs. EVOO diet at the end of the experimental period. EVOO-fed mice showed less incidence and multiplicity of tumors than in those SFO-fed mice. ß-catenin immunostaining was limited to cell membranes in control groups, whereas translocation from the cell membrane to the cytoplasm and/or nucleus was showed in DSS-treated groups and its expression was higher in SFO-fed animals. Cytokine production was significantly enhanced in SFO-fed mice, while this increase was not significant in EVOO-fed mice. Conversely, cyclooxygenase-2 (COX-2) and inducible nitric oxidase synthase (iNOS) expression were significantly lower in the animal group fed with EVOO than in the SFO group. CONCLUSIONS: These results confirm that EVOO diet has protective/preventive effect in the UC-associated CRC. This beneficial effect was correlated with a better DAI, a minor number of dysplastic lesions, a lower ß-catenin immunoreactivity, a proinflammatory cytokine levels reduction, a non modification of p53 expression and, COX-2 and iNOS reduction in the colonic tissue.


Subject(s)
Adenocarcinoma/prevention & control , Colitis, Ulcerative/physiopathology , Colon/physiopathology , Colonic Neoplasms/prevention & control , Dextran Sulfate/adverse effects , Plant Oils/pharmacology , Animals , Colitis, Ulcerative/prevention & control , Colorectal Neoplasms/prevention & control , Dextran Sulfate/administration & dosage , Diet , Disease Models, Animal , Female , Inflammation/prevention & control , Mice , Mice, Inbred C57BL , Olive Oil , Plant Oils/chemistry , Plant Oils/metabolism , Sunflower Oil
10.
Peptides ; 29(11): 2001-12, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18708104

ABSTRACT

Adrenomedullin (AM) is a 52 amino acid peptide and member of the calcitonin gene-related peptide (CGRP) super family. Given that AM has emerged as a potential immuno-regulatory and anti-inflammatory agent in various experimental models, this study has deepened into its possible therapeutic effect in intestinal inflammation analyzing the responses in both acute and chronic (14 and 21 days) phases of TNBS-induced colitis in rats. In the acute model, AM treatment reduced the incidence of diarrhea and the severity of colonic damage, and improved the survival rate at the three doses assayed (50, 100, and 200ng/kg animal). AM administration was able to reduce the early production of TNF-alpha and collaborated to maintaining basal levels of IFN-gamma and IL-10. In the chronic studies the peptide attenuated the extent of the damage with lesser incidence of weight loss and diarrhea (50 and 100ng/kg animal). Cellular neutrophil infiltration, with the subsequent increase in myeloperoxidase (MPO) levels caused by TNBS, was reduced after chronic AM administration. The peptide played a role in the evolution of Th1/Th2 cytokines balance and chronic disease recuperation: levels of proinflammatory TNF-alpha and IFN-gamma decreased and anti-inflammatory IL-10 increased significantly. Cyclooxygenase-2 (COX-2) and nitric oxide synthase (iNOS) protein expression were not modified by AM administration, although a reduction of nitric oxide (NO) production could be detected in the chronic model. These results support a role of AM as an anti-inflammatory factor with beneficial effects in intestinal inflammatory colitis.


Subject(s)
Adrenomedullin/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Acute Disease , Animals , Chronic Disease , Colitis/chemically induced , Colitis/drug therapy , Colitis/pathology , Colon/drug effects , Colon/pathology , Female , Interferon-gamma/metabolism , Interleukin-10/metabolism , Male , Peroxidase/metabolism , Rats , Rats, Wistar , Trinitrobenzenesulfonic Acid , Tumor Necrosis Factor-alpha/metabolism
11.
Curr Pharm Des ; 14(1): 71-95, 2008.
Article in English | MEDLINE | ID: mdl-18220820

ABSTRACT

About 50 peptides, and a similar number of peptide receptors, are known to be present in the gut and this amount is likely to rise significantly over the next few years. While there has been a massive research effort to define their functions and their anatomical distribution in the central nervous system (CNS), the understanding of their roles in the gut is far more limited. Classically, the physiological functions include the control of motility, fluids, electrolytes, and digestive enzymes secretion, or vascular and visceral pain function, and more recently, the role-played in cell proliferation and survival, and in immune-inflammatory responses. The term inflammatory bowel disease (IBD) that encompasses Crohn's disease and ulcerative colitis, is clearly an inflammatory disease where several mediators such as cytokines, chemokines, prostanoids, nitric oxide or free radicals, produced by infiltrating cells, play a critical role in intestine tissue alteration. Some peptides, initially known for their neuroregulative properties, have been suggested to act as endogenous immune factors, with predominant antiinflammatory effects. Based on these actions, these molecules are proposed as potential agents for the treatment of IBD and selective peptide analogs are being developed as novel therapeutic strategies for IBD patients. Patients with IBD have an increased risk for developing colorectal cancer (CRC). Up to the present time, no known genetic basis has been identified to explain CRC predisposition in these IBD. Instead, it is assumed that chronic inflammation is what causes cancer. This is supported by the fact that colon cancer risk increases with longer duration of colitis, greater anatomic extent of colitis, the concomitant presence of other inflammatory manifestations, and the fact that certain drugs used to treat inflammation, may prevent the development of CRC. However, though different regulative peptides play a beneficial role in experimental IBD, an increasing number of articles about cancer pathology are starting to implicate different peptides in tumor initiation and progression. The complexities of cancer could be described in terms of a small number of underlying principles and the malignant growth is dependent upon a multi-step process including different basic essential alterations. The activities of many peptides that are overexpressed in cancer cells help them to develop several of the molecular and physiological features that are now considered the basis of malignant growth. These collective findings implicate regulative peptides, receptors, or peptide-levels modulators, as important biological targets for developing intervention strategies against intestinal immunological disorders and cancers.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Inflammatory Bowel Diseases/drug therapy , Peptides/pharmacology , Animals , Anti-Inflammatory Agents/immunology , Anti-Inflammatory Agents/therapeutic use , Colorectal Neoplasms/etiology , Colorectal Neoplasms/immunology , Drug Delivery Systems , Gene Expression Regulation , Humans , Inflammation/drug therapy , Inflammation/immunology , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/immunology , Intestines/immunology , Peptides/immunology , Peptides/therapeutic use
12.
Farm. aten. prim ; 5(4): 128-132, oct.-dic. 2007.
Article in Spanish | IBECS | ID: ibc-122132

ABSTRACT

Objetivo. Detectar y cuantificar el grado de cumplimiento terapéutico en pacientes mayores, residentes en una institución geriátrica asistida y valorar el seguimiento farmacoterapéutica y la interención por parte del farmacéutico como herramienta útil para mejorar dicho cumplimiento. Método: El estudio se realizó en pacientes fueron entrevistados por un farmacéutico, individualmente, utilizando un cuestionario validado. El grado de incumplimiento se calculó comparando las respuestas de las encuestas de los pacientes frente a las prescripciones médicas, facilitadas por los facultativos. Posteriormente, se efectuó una intervención informativa/educativa. Resultados: el grado de incumplimiento fue del 57%, relacionado directamente con grupos terapéuticos más afectados, éstos resultaron ser, de mayor a menor, los siguientes: antihipertensivos, antiácidos, analgésicos, antagonistas del calcio, psicoclépticos, hipolipemiantes, activos en terapia cardiaca y antitrombóticos. Entre las causas de incumplimiento destacaron las siguientes: olvido (34,1%), dosificación incorrecta (28,4%), desconocimiento del objetivo del tratamiento (23,9%), despreocupación sobre el propio estado de salud (9,1%) y aparición de reacciones adversas (4,6%). En el 100% de los casos intervenidos se consiguió un cumplimiento correcto o una mejora. Conclusiones: En los pacientes mayores institucionalizados, la ayuda farmacéutica consistente en el seguimiento, la información y el asesoramiento sobre sus tratamientos favorece el cumplimiento terapéutico, lo que conduce a mejorar la efectividad, reducir los riesgos y disminuir el gasto, lo que sin duda contribuye a un uso más racional del medicamento (AU)


Objective: To detect and quantify the degree of compliance with treatment among elderly residents of an assisted-living facility and to assess the utility of the follow-up of pharmaceutical care and the intervention on the part of the pharmacist as a tool to improve adherence to treatment. Methods: The study involve the residents of the Heliópolis Geriatric Institution over 65 years of age (n=77) of both sexes. The subjects were interviewed individually by a pharmacist, who employed a validated questionnaire. The degree of noncompliance was calculated by comparing the responses to the surveys with the drug prescriptions provided by the attending physician. Subsequently, an informative/educational intervention was carried out. Results: The rate of noncompliance was 57% and was directly related to the age of the individual and the number of drugs prescribed; there was also a minor association with the female sex. The drug treatments most widely affected, in descending order of importance, were antihypertensive agents, antacids, calcium antagonists, tranquilizers, lipid-lowering agents, cardiac medications and, finally, antithrombotic agents. The major reasons for noncompliance were forgetfulness (34.1%), dosing errors (28,4%), lack of knowledge about the purpose of the treatment (23,9%), lack of concern as to the health status of the patient himself (9.1%) and the development of adverse reactions (4.6%). Correct compliance and an improvement in adherence to treatment were achieved in 100% of the cases. Conclusions. In elderly institutionalized patients, pharmaceutical care consists of follow-up, information and advice on their treatments. In favors treatment compliance, which leads to an improvement in the efficacy of therapy, reduces risks and lowers costs, outcomes that undoubtedly contribute to a more rational use of medications (AU)


Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Chronic Disease/drug therapy , Medication Adherence/statistics & numerical data , Drug Therapy, Combination , Health of Institutionalized Elderly , Evaluation of the Efficacy-Effectiveness of Interventions
13.
J Ethnopharmacol ; 114(2): 153-60, 2007 Nov 01.
Article in English | MEDLINE | ID: mdl-17884315

ABSTRACT

Guazuma ulmifolia Lam., a member of the Sterculiaceae family, is used in folk medicine because of its antioxidant, antimicrobial and antihypertensive properties. Most of the research work carried out on this plant has focused on the bark because of its high concentration of antioxidant proanthocyanidins. The flowers and leaves of Guazuma ulmifolia, though less studied, are also used as a remedy for different conditions, such as kidney and gastrointestinal diseases, fever and diabetes. The aim of this study was to assess the gastroprotective effects of an aqueous suspension of the ethanolic extract from leaves and flowers of Guazuma ulmifolia in a model of acute gastric ulcer induced by diclofenac as ulcerogenic agent, using the proton pump inhibitor omeprazole as a protection reference. Therefore, the extract was administered two times orally to three groups of Wistar rats at doses of 500, 250 and 125mg/kg, with a 24-h interval between doses. Diclofenac (100mg/kg) was given 1h after the last administration of the extract. Pretreatment with Guazuma ulmifolia or omeprazole decreased the ulcerated area in a dose-dependent way. Myeloperoxidase activity as a marker of neutrophil infiltration was slightly reduced in vivo, whereas in vitro, anti-inflammatory activity was clearly inhibited in a dose-dependent way. The lowest doses of the extract significantly decreased the levels of lipoperoxides, and superoxide dismuthase activity increased to a similar extent as with omeprazole (P<0.001). Examination of glutathione metabolism reflected a significant rise in glutathione peroxidase activity at the highest dose of Guazuma ulmifolia. Finally, there was a faint elevation in prostaglandin E(2) levels with all doses, though the depletion induced by diclofenac could not be reverted. We conclude that the aerial parts of Guazuma ulmifolia protect gastric mucosa against the injurious effect of NSAIDs mainly by anti-inflammatory and radical-scavenging mechanisms.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/antagonists & inhibitors , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Anti-Ulcer Agents , Malvaceae/chemistry , Stomach Ulcer/chemically induced , Stomach Ulcer/prevention & control , Animals , Diclofenac , Dinoprostone/metabolism , Female , Flowers/chemistry , Gastric Mucosa/metabolism , Gastric Mucosa/pathology , Glutathione/metabolism , Glutathione Peroxidase/metabolism , Leukocytes/drug effects , Leukocytes/enzymology , Lipid Peroxidation/drug effects , Male , Neutrophil Infiltration/drug effects , Omeprazole/pharmacology , Peroxidase/metabolism , Plant Extracts/pharmacology , Plant Leaves/chemistry , Rats , Rats, Wistar , Sulfhydryl Compounds/metabolism , Superoxide Dismutase/metabolism
14.
Curr Pharm Des ; 13(9): 933-62, 2007.
Article in English | MEDLINE | ID: mdl-17430191

ABSTRACT

Poly(ADP-ribose) polymerase (PARP) comprise of a family of enzymes which catalyses poly(ADP-ribosyl)ation of DNA-binding proteins. To date, seven isoforms have been identified: PARP-1, PARP-2, PARP-3, PARP-4 (Vault-PARP), PARP-5 (Tankyrases), PARP-7 and PARP-10 with structural domains and different functions. PARP-1, the best characterised member, works as a DNA damage nick-sensor protein that uses beta-NAD(+) to form polymers of ADP-ribose and has been implicated in DNA repair, maintenance of genomic integrity and mammalian longevity. The generation of free radicals, reactive oxygen species, and peroxynitrite causes overactivation of PARP resulting in the depletion of NAD(+) and ATP and consequently in necrotic cell death and organ dysfunction. PARP has also been involved in the up-regulation of numerous pro-inflammatory genes through the activation of several transcription nuclear factors. Thus, PARP plays an important role in the pathogenesis of several diseases, such as, stroke, myocardial infarction, circulatory shock, diabetes, neurodegenerative disorders, including Parkinson and Alzheimer diseases, allergy, colitis and other inflammatory disorders. Pharmacological modulation of PARP activity may constitute a suitable target to enhance the cytotoxicity of certain DNA-damaging anticancer drugs. Also, PARP inhibition may be a viable strategy to control viral infections. This review is intended to provide an appreciation of new pharmacological perspectives of these remarkable drugs, summarize novel underlying mechanisms and discuss their potential clinical implications.


Subject(s)
Antineoplastic Agents , Enzyme Inhibitors , Hypoglycemic Agents , Poly(ADP-ribose) Polymerase Inhibitors , Protective Agents , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Clinical Trials as Topic , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Humans , Hypoglycemic Agents/pharmacology , Hypoglycemic Agents/therapeutic use , Poly(ADP-ribose) Polymerases/genetics , Poly(ADP-ribose) Polymerases/physiology , Protective Agents/pharmacology , Protective Agents/therapeutic use , Protein Subunits
15.
Regul Pept ; 141(1-3): 96-104, 2007 Jun 07.
Article in English | MEDLINE | ID: mdl-17331599

ABSTRACT

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder considered as a consequence of an aberrant response of the immune system to luminal antigens. Numerous groups of agents are being evaluated as novel therapeutic approaches for its treatment; in this way, different peptides have emerged as potential candidates. Galanin is an active neuropeptide distributed in the central and periphery nervous systems although it has been also described having important autocrine and paracrine regulatory capacities with interesting inflammatory and immune properties. In this line, we have observed that galanin treatment has a significant preventive effect in the experimental trinitrobenzensulfonic acid (TNBS) acute model of inflammatory colitis. The aim of the present study was to investigate intensively the role played by the peptide in the evolution of the inflammatory pathology associated to IBD. Galanin (5 and 10 microg/kg/day) was administered i.p., daily, starting 24 h after TNBS instillation, and continuing for 14 and 21 days. The lesions were blindly scored according to macroscopic and histological analyses and quantified as ulcer index. The results demonstrated that chronic administration of galanin improved the colon injury than the TNBS induced. The study by Western-blotting of the expression of nitric oxide inducible enzyme (iNOS), as well as the total nitrite production (NO) assayed by Griess-reaction, showed significant reduction associated with peptide administration. The number of mast cells was also identified in histological preparations stained with toluidine blue and the results showed that samples from galanin treatment, mostly at 21 days, had increased the number of these cells and many of them had a degranulated feature. In conclusion, chronic administration of galanin is able to exert a beneficial effect in the animal model of IBD assayed improving the reparative process. Participation of nitric oxide pathways and mucosal mast cells can not be discarded.


Subject(s)
Colitis/drug therapy , Colitis/pathology , Galanin/administration & dosage , Galanin/pharmacology , Galanin/therapeutic use , Animals , Blotting, Western , Colitis/chemically induced , Cyclooxygenase 2/biosynthesis , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Galanin/metabolism , Injections, Intraperitoneal , Male , Mast Cells/drug effects , Nitric Oxide Synthase Type II/biosynthesis , Nitrites/analysis , Peroxidase/analysis , Rats , Rats, Wistar , Time Factors , Trinitrobenzenesulfonic Acid/toxicity , Tumor Necrosis Factor-alpha/biosynthesis
16.
Histol Histopathol ; 20(2): 437-47, 2005 04.
Article in English | MEDLINE | ID: mdl-15736048

ABSTRACT

The objective of the present study has been to advance knowledge of the gastric role played by the amino acid L-Arginine (L-Arg) in the evolution of a chronic gastric ulcer. In order to clarify it, L-Arg alone or together with Ibuprofen have been administrated in an experimental acetic acid chronic ulcer, analysing characteristic parameters of an active curative process, such as PGE2 production, COX expression, and also angiogenesis, proliferation/apoptosis and growth factors expression. Our results reveal that L-Arg is favourable in the healing process improving the curative course. Ibuprofen caused a delay in ulcer healing, more evident 14 days after ulcer induction; COX-2 expression was increased at the 7th day although no signal of protein could be detected after 14 days; PGE2 production was inhibited in intact and ulcerated areas at both times assayed. In contrast, treatment with L-Arg reduced the delay of the lesion, the increment in COX-2 expression induced by Ibuprofen, and was able to maintain PGE2 levels similar to the control group after 14 days. Additionally, the histological study showed that the healing effects of L-Arg might be associated with an increased angiogenesis and FGF-2 expression. These actions could be considered key factors in the healing response associated with L-Arg administration. However, the proliferation study assayed with the PCNA-immunostaining method did not reveal significant differences, as the same as the apoptosis analysis. In conclusion, the coupling of L-Arg to Ibuprofen is an attractive alternative to Ibuprofen administration alone because it not only attenuates but also improves the evolution of chronic lesions through mechanisms that implicate endogenous PG and FGF-2-associated pathways, which allow an increase of angiogenesis process.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Arginine/administration & dosage , Growth Substances/metabolism , Ibuprofen/administration & dosage , Ibuprofen/toxicity , Prostaglandin-Endoperoxide Synthases/metabolism , Stomach Ulcer/drug therapy , Acetic Acid/toxicity , Animals , Chronic Disease , Cyclooxygenase 1 , Cyclooxygenase 2 , Dinoprostone/biosynthesis , Fibroblast Growth Factor 2/metabolism , Male , Membrane Proteins , Neovascularization, Pathologic , Rats , Rats, Wistar , Stomach Ulcer/chemically induced , Stomach Ulcer/enzymology , Stomach Ulcer/pathology , Vascular Endothelial Growth Factor A/metabolism , Wound Healing/drug effects
17.
Curr Pharm Des ; 10(28): 3505-24, 2004.
Article in English | MEDLINE | ID: mdl-15579048

ABSTRACT

The peroxisome proliferator-activated receptor gamma (PPARgamma), a member of the nuclear hormone receptor superfamily has classically been characterized for its implications in adipocyte differentiation and fat metabolism. Recently, PPARgamma has been implicated in the pathophysiology of inflammatory and immune responses possibly through inhibition of the mitogen-activated protein kinase (MAPK) pathways or the activation of the transcription nuclear factor kappa B (NF-kappaB). Thus, these agents might also have therapeutic potential in the treatment of gastrointestinal inflammatory disorders, such as ulcerative colitis and Crohn's disease. The synthetic thiazolidinediones (TZDs), a novel class of insulin-sensitizing drugs, were the first class of compounds identified as PPARgamma ligands, and represent a significant advance in anti-diabetic therapy. However, there is less information about endogenous ligands, although the prostaglandin (PG)J(2) and the oxidized phosphatidylcholine have been suggested. Furthermore, PPARgamma ligands have been shown to be potent inhibitors of angiogenesis, a process necessary for tumor growth and metastasis, and protect against cellular transformation. Further work is needed to establish in detail the anti-proliferative and pro-differentiation mechanisms of PPARgamma activators and their efficacy in certain cancers.


Subject(s)
PPAR gamma/agonists , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Antirheumatic Agents/pharmacology , Antirheumatic Agents/therapeutic use , Clinical Trials as Topic , Diabetes Mellitus, Type 2/drug therapy , Digestive System Diseases/drug therapy , Digestive System Diseases/metabolism , Humans , Insulin Resistance/physiology , Ligands , PPAR gamma/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...